2026-08-25

Interim report Q2 2026

”The second quarter of 2026 was characterized by a continued strong focus on advancing the clinical development of our drug candidate arfolitixorin toward becoming a new cornerstone of cancer treatment. During the quarter, we placed additional emphasis on optimizing the study design and accelerating patient recruitment. With a newly opened investigational site in Germany in the third quarter and approval from the Safety Review Committee to initiate the highest dose-escalation cohort of 500 mg/m², we are shifting into a higher gear as we advance toward the phase II part of the study.” says CEO, Petter Segelman Lindqvist.